Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis

(2017) G. G. Song et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

(2016) Christopher J Edwards et al.   ANNALS OF THE RHEUMATIC DISEASES

Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis

(2016) Patompong Ungprasert et al.   CLINICAL RHEUMATOLOGY

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

(2016) M. Cutolo et al.   JOURNAL OF RHEUMATOLOGY

Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis

(2016) Patompong Ungprasert et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

(2015) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

(2015) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Ranking treatments in frequentist network meta-analysis works without resampling methods

(2015) Gerta Rücker et al.   BMC Medical Research Methodology

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Work Productivity Loss and Fatigue in Psoriatic Arthritis

(2014) J. A. Walsh et al.   JOURNAL OF RHEUMATOLOGY

Network Meta-Analysis Using R: A Review of Currently Available Automated Packages

(2014) Binod Neupane et al.   PLoS One

Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report

(2014) Jeroen P. Jansen et al.   VALUE IN HEALTH

Conceptual and Technical Challenges in Network Meta-analysis

(2013) Andrea Cipriani et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Partial order methodology: a valuable tool in chemometrics

(2013) L. Carlsen et al.   JOURNAL OF CHEMOMETRICS

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Network meta-analysis, electrical networks and graph theory

(2012) Gerta Rücker   Research Synthesis Methods

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis

(2011) Troy Noordenbos et al.   ARTHRITIS AND RHEUMATISM

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone

(2011) C. F. Rosen et al.   RHEUMATOLOGY

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

(2010) Philip Mease et al.   ARTHRITIS AND RHEUMATISM

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

(2010) S Prey et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

(2009) MA Radtke et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

(2008) Camilla Jandus et al.   ARTHRITIS AND RHEUMATISM